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Abstract 
BACKGROUND: Repetitive traumatic brain injury (RTBI) has gained much attention in this decade, especially in 
contact sports athletes and military personals. This injury is correlated with early neurodegenerative changes that 
are marked with the increased of tau protein. Turmeric extract (TE) is a well-known anti-inflammation and 
antioxidant that decreases tau protein expression in neurodegenerative disease.  
AIM: This study aimed to prove the effect of TE on tau protein level after RTBI.  
METHODS: Forty Sprague Dawley mice were divided into four groups, i.e. negative sham control group, the 
control group, and two treatment groups. A weight drop model was used by applying a 40-gram mass that was 
dropped from a 1-meter height onto the vertex of the head, with a total frequency of 12 times, divided into 4 days 
(day 0, 1, 3, and 7; 3 traumas on each day). TE was given to all treatment groups with 500 mg/kg BW doses once 
daily. The first treatment group had TE for seven days along the trauma. The second treatment group had 
pretreatment TE extract, given from seven days before first trauma and continued along the trauma protocol days. 
Tau protein level was measured on brain and serum using ELISA method.  
RESULTS: There was a significant reduction of tau protein level in both treatment groups compared to trauma 
group, either in serum or brain, but we also found significant differences regarding brain tau level between the 
treatment and pretreatment group.  
CONCLUSION: This study might provide evidence of with the role of pretreatment TE in RTBI. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Repetitive traumatic brain injury (RTBI), 
particularly concussion, is frequently happened in 
some populations, like contact sports athletes and 
military personals. In a survey involving 222 
professional football players, the incident of head 
impact is very diverse, from four times to 125 times in 
two weeks. Another report said that around 30% of 
football players do heading for more than 1000 times 
annually [1]. In the military, it is estimated that up to 
35% of American service personnel in Iraq and 
Afghanistan have sustained a concussion [2]. Almost 
all sports-related traumatic brain injury is minor, with 
spontaneous recovery within days to weeks, even a 
small number of individuals develop long-lasting and 
progressive symptoms.  
Following traumatic brain injury, even in 
mildest form, ionic flux, hyper glycolysis, and 
metabolic uncoupling will result in an energy crisis that 
can be lasted until 7 to 10 days [3]. The time needed 
for recover may render the brain vulnerable to the 
second event. RTBI has been shown they exacerbate 
the impairment of the brain’s cellular oxidative 
metabolism similar to severe traumatic brain injury [4]. 
RTBI itself will result in progressive white matter injury 
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and behavioural dysfunction [5]. Around 17% of 
individuals with RTBI will develop a constellation of 
several dysfunctions in behaviour, mood, cognitive, 
and motoric [6]. Over the last several decades, it is 
known that these symptoms are correlated with 
progressive neurodegeneration process that happens 
in this population. This early neurodegenerative 
process is named chronic traumatic encephalopathy 
(CTE). The epidemiology of CTE is unknown since 
microscopic examination after an autopsy is the only 
widely accepted way to diagnose this condition [7].  
As in another neurodegenerative process, 
there are several proteinopathies that can be found in 
CTE. Protein tau is the main proteinopathy. 
Hyperphosphorylation will dissociate tau from tubulin 
and expose new phosphorylation site. In this state, 
protein tau will be insoluble, accumulated into 
oligomers and neurofibrillary tangles [8]. This 
condition resembles Alzheimer’s disease (AD), with 
different in tau distribution. In CTE, tau is most 
commonly found in the superficial layer, compared to 
layers III and V in AD [9] [10]. Factors that initiate the 
development of tau pathology are still unknown but 
associated with chronic neuroinflammation. 
Neuroinflammation is a common finding after TBI, 
especially in moderate and severe TBI. In mild TBI, 
neuroinflammation is usually short-lived, but RTBI 
may lead to chronic neuroinflammation due to self-
perpetuating inflammatory cycle, including the 
sustained release of inflammatory mediators. It is 
shown that microglial neuroinflammation contributes 
to tau accumulation in CTE [11].  
To this date, there is no approved therapy for 
CTE. Rest and symptomatic therapy are the main 
treatment approaches. The answer may lie in 
understanding the principle of tau proteins, where tau 
proteins aggregate through nucleation, templating, 
growth, multiplication, and spread. Each of these 
mechanisms represents a potential target for 
therapeutic intervention. Therapies that target tau 
phosphorylation, tau aggregation, and microtubule 
stabilisation are already in clinical trials [12].  
For a long time, practitioners of Ayurvedic, 
traditional Chinese medicine, and Southeast Asian 
medicine have used turmeric root extract (TE) for the 
culinary, religious, and medical condition. Curcumin, 
the major active compound of TE, is a strong anti-
inflammatory and antioxidant properties [13]. The use 
of curcumin in the AD has been studied extensively. 
Curcumin reduces accumulation of soluble tau 
aggregates via inhibition the kinase [14]. Even so, all 
human clinical trials fail to prove the role of curcumin 
in the AD, regarding cognitive function [15]. The main 
problem is curcumin’s low bioavailability [16].  
The present study was undertaken to 
evaluate the effects of turmeric extract in RTBI 
concerning protein tau level, both in brain and plasma.  
 
Materials and Methods 
 
The subjects of this experiment were 6-8 
weeks old Sprague Dawley rats weighing 300-350 g 
(n = 40). This experimental protocol was approved by 
an Institutional Ethics Committee in Universitas 
Sumatera Utara, Medan, Indonesia. The animals were 
housed with 12 h light/12 h cycle and given access to 
food and water ad libitum.  
The animals were exposed to the weight-drop 
model of TBI that had been described before [17]. A 
40 g mass was dropped from 1 m high unto the 
vertex. A 2.5 cm metal plate was placed on the vertex 
to prevent skull fracture. The total cumulative traumas 
were 12 times, divided 3 times each day on day 0, 1, 
3, and 7. We did not use anaesthesia in this protocol.  
The rats were randomly allocated into four 
groups (n = 10) as follow: a control (sham-operated) 
group, a trauma group, and two group treatments, i.e., 
treatment 1 (after trauma), and treatment 2 
(pretreatment) groups. The control group underwent 
neither trauma nor TE. The trauma group underwent 
trauma only, but no TE. The first treatment group 
received TE for seven days along the trauma and the 
second treatment group received TE started from 
seven days before the trauma and along the trauma.  
Turmeric extract (Sido Muncul, Indonesia, 
18% curcumin) was suspended in distilled water and 
administered to animals via oral gavage in 2 cc 
solution. Turmeric extract was given per oral with 
dose 500 mg/kgBW once daily. The animals were 
weighed after the acclimatisation. Turmeric extract 
was administered in the morning, 1 hour before the 
first trauma.  
As a marker of neurodegenerative process, 
we investigated AT-8 expression. The expression of 
all markers was investigated on paraffin-embedded 
sections using the avidin-biotin-peroxidase complex 
method. Four-millimetre-thick paraffin sections were 
dewaxed, rehydrated, and microwave for 10 minutes. 
The endogenous peroxidase activity of the 
investigated specimens was blocked with 3 per cent 
H2O2 for 10 minutes, followed by 25 minutes washing 
with phosphate-buffered saline (PBS). The tissue 
sections were incubated with normal rabbit serum for 
10 minutes, and then the slides were incubated at 
room temperature with monoclonal mouse AT-8 
(Santa Cruz). Sections were washed with PBS and 
incubated with a secondary antibody for 30 minutes. 
Sections were washed twice with PBS, developed 
with 0.05% 3, 3 diamino-benzinetetrahydrochloride for 
five minutes, and slightly counterstained.  
All samples were evaluated by the first author 
(not blinded to specimen). A positive signal for AT-8 in 
brain tissue was quantitatively estimated by the 
distribution of positively stained cells in the cortical 
brain. Cell counts were carried out using a light 
 Siahaan et al. Turmeric Extract Supplementation Reduces Tau Protein Level in Repetitive Traumatic Brain Injury Model 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci. 2018 Nov 25; 6(11):1953-1958.                                                                                                                                                1955 
 
binocular microscope with 1000 times magnification in 
20 high power fields.  
Protein tau level was measured in plasma and 
brain. Animals were sacrificed one day after the last 
protocol day. After anaesthesia, rats were 
decapitated, and brains were dissected. Brain tissues 
were homogenised in ice-cold homogenization buffer 
(50 mM Trizma base/HCl buffer, pH 7.4 containing 
protease inhibitors and    M of the phosphatase 
inhibitor okadaic acid), these brain homogenates were 
placed in - 0°C.  
Blood was taken from the left ventricle. After 
collection of the whole blood, blood was left 
undisturbed at room temperature for 15-30 minutes. 
The clot was removed by centrifuging at 1,000-2,000 x 
g for 10 minutes. The plasma then was maintained at 
-20°C. Blood and plasma levels of total tau were 
determined using a commercially available sandwich 
ELISA system (Cusabio). 
Values were expressed as means  SD. The 
results were computed statistically using one-way 
analysis of variance for each group. The Tuckey post 
hoc testing was performed for intergroup 
comparisons. A difference was considered significant 
at the p < 0.05 level.  
 
 
Results 
 
There was no mortality rate in this protocol. 
We also did not find a decrease in body weight (Table 
1). There was no significant difference regarding body 
weight on all three groups (Table 1), either in negative 
sham control group (377.22  29.72 gr vs. 378.44  
29.66 gr), trauma group (351.78  29.89 gr vs. 349.33 
 38.90 gr), or in treatment group (367.89  36.70 gr 
vs. 357.89  39.89 gr). 
Table 1: Weight changes in subjects (Mean  SD) 
Group Day 0 (gr) Day 7 (gr) p 
Negative sham  377.22  29.72 378.44  29.66 0.910 
Trauma 351.78  29.89 349.33  38.90 0.482 
Treatment 367.89  36.70 357.89  39.89 0.950 
Paired t-test. Significant if p < 0.05 
  
There was significantly difference between 
tau level between the negative sham group and 
trauma group, either in the brain (Figure 1A) or 
plasma (Figure 1B). In the negative sham control 
group, brain protein tau level was 4.21  0.22 pg/ml 
while plasma tau protein level was 4.36  0.13 pg/ml). 
There was significant increase of tau protein level 
following RTBI, either in brain (17.76  2.06 ng/ml, p < 
0.05) or plasma (6.16  1.11 ng/ml, p < 0.05).  
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Figure 1: Change in protein tau level following RTBI in the brain (A) 
and plasma (B). There was significant protein tau level difference 
between trauma and negative sham group both in the brain and in 
plasma. Data was shown as Mean  SD. T-test; significant if p < 
0.05 
 
There was a significant decrease of tau 
protein level in both treatment groups compared to the 
trauma group, either in the brain (Figure 2A) or in 
plasma (Figure 2B). In treatment 1 group, the brain 
tau protein level was 13.31  1.45 pg/ml and the 
plasma tau protein level was 5.25  0.77 pg/ml.  
These were significantly different compared to 
in trauma group (p < 0.05). In treatment 2 group, 
either brain tau protein level (3.60  0.23 pg/ml) or 
plasma tau protein level (4.99  0.53 pg/ml) was also 
significantly different compared to trauma group (p < 
0.05). There was significant brain tau protein level 
between treatment 1 group and treatment 2 group, 
which was not seen at the plasma.  
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Figure 2: Change in protein tau level after TE supplementation on 
the brain (A) and plasma (B). There was significant protein tau level 
difference among either treatment 1 or treatment 2 group with 
trauma group in brain and plasma. There was also a significant 
difference regarding protein tau level between treatment 1 and 
treatment 2 group in bran. The significant difference was not found 
in plasma. Data was shown as Mean  SD. T-test; significant if p < 
0.05  
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Discussion 
 
We reported no mortality rate in this protocol. 
Xu et al., (2006) report the same finding. The mortality 
rate is increased along the increased weight and 
height. With the 50 g-1 m impact, mortality is 18.2%, 
and with the 60 g-1 m impact, mortality is increased 
up to 40% [17].  
We also did not find a decrease in body 
weight (Table 1). In this RTBI model, the animals 
underwent injury schedule at days 0, 1, 3, and 7, with 
three hits daily. It made a total of 12 TBI events. The 
use of this model was meant to replicate the pattern of 
multiple concussion in contact sports athlete. This 
model did not show evidence of weight loss, 
compared to the more “severe” model. Samini et al., 
(2013) find significant weight decrease following a 
weight-drop model of TBI. The body weight decrease 
was probably due to injury affecting feeding behaviour 
and injury to the anterior hypothalamus, even though 
multi-factorial mechanisms are involved in TBI [18]. 
Tau is a soluble intracellular protein with little 
secondary structure. One of protein tau’s functions is 
to modulate the stability of microtubules. Tau is 
localised in neuronal cells, but it is not released. 
Therefore, CSF and blood tau levels in healthy 
subjects are expected to be low or non-existent.  
In pathologic conditions, associated with 
tauopathy, the soluble protein tau becomes 
hyperphosphorylated at specific site forming an 
insoluble form. The brains of some individuals who 
experience RTBI and develop CTE display tauopathy, 
predominantly perivascular and in the cortex [19]. 
Several pathogenic mechanisms have been 
suggested to contribute to this tau-specific pathology 
profile, include an imbalance in the activity levels of 
the tau-specific kinase, dysfunction in protein 
clearance mechanism, prolonged neuroinflammation, 
and increased genetic susceptibility (ApoE4 allele) 
[20]. Increased of protein tau’s level in the brain is 
reported in neurodegenerative diseases, such as AD 
(21). High protein tau level is also found in the brain’s 
interstitial fluid [22], CSF [23], and blood [24]. 
Neselius et al., (2013) reported that tau 
plasma levels were significantly increased in Olympic 
boxers, even without a symptom of concussion [25]. In 
mild TBI, tau is a poor predictor of CT lesions and 
post-concussion syndrome [26]. There are 
inconsistencies regarding the evaluation of protein tau 
across the literature, i.e. in the form of cleaved-tau, 
total-tau, and phosphorylated tau. This inconsistency 
may also be a result of many factors, including the 
sensitivity and specificity of the tau assays used and 
the timing of the sample [27]. 
Penetration of protein tau into the blood 
suggested that this protein might enter the circulation 
through the blood-brain barrier (BBB) disruption. 
Although the integrity of BBB was not assessed, the 
disruption of BBB in the previous report with the same 
trauma protocol was minimal [17]. Kane et al., (2012) 
also reported minimal BBB disruption when using 95-g 
mass dropped from a 1.5-m height [28]. Other 
hypotheses that could be proposed are release via 
glymphatic system or a more complex intracellular 
transport via macrophages of phagocytic microglia 
(24). However, these hypotheses require further 
studies.  
However, the mechanism behind tau 
pathology in repetitive concussive head injury is 
unknown. Although protein tau is widely used as a 
biomarker for the diagnosis of CTE, it is not yet clear 
that tau is the principal mediator of pathogenesis. 
Protein tau deposition could be just a result of 
cumulative biochemical changes that happen after 
RTBI [29].  
In this study, treatment groups were divided 
into two groups. The first treatment group received TE 
along the trauma for seven days. The second group 
was pretreatment group that received TE seven days 
before the trauma was started and continued along 
the trauma. Protein tau level was significantly lower in 
either first or second treatment group compared to the 
trauma group. Nevertheless, protein tau level on the 
brain was significantly lower on the second treatment 
group compared to the first. The same difference was 
not found in plasma (Figure 2A and 2B).  
The potential role of TE in degenerative 
disease is supported by epidemiological evidence. It is 
reported that people age 70-79 years old in India has 
a 4.4-fold less prevalence of AD compared to the 
same population age in the US. The regular intake of 
turmeric in common Indian diet has been thought as 
the primary reason for this finding [30]. In Singapore, it 
was also found that people who regularly ate curry 
have better cognitive performance than people who 
rarely or never ate curry [31]. 
Curcumin was shown to affect protein kinase 
modulation, such as Akt [32], JNK [33], and GSK-3 
[34]. Since protein kinase has a crucial role in protein 
tau phosphorylation, it may explain why tau protein 
level was significantly decreased in both treatment 
group. In neurodegenerative disease, there is also 
dysfunction in molecular chaperone. Molecular 
chaperones, such as heat shock proteins (HSPs), play 
a significant role in the removal of misfolded or mutant 
proteins. Curcumin affects augmenting expression or 
function of HSPs in the cell [35]. The anti-
inflammatory properties of curcumin also play a 
significant role in this effect. Curcumin also induces 
M2 macrophage polarisation in experimental 
autoimmune myocarditis [36]. M2 macrophages are 
associated with the production of anti-inflammatory 
cytokines, increased phagocytic activity, as well as 
regulation of tissue repair and remodelling [37]. 
In this research, we found significant protein 
tau level difference between the first and second 
treatment group. The second treatment group was a 
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pre-treatment group that received TE for one week 
before TBI. Curcumin retreatment will induce Nrf2 that 
is a regulator of cellular resistance to oxidants [38]. In 
a model of traumatic brain injury, curcumin pre-
treatment also decreases malondialdehyde 
expression, decreases the lesion size, and improves 
neurological function [18]. This finding might also 
support the role of curcumin as a neuroprotective 
agent, not as a treatment agent. It also could explain 
the reason behind the failure of curcumin in a human 
study regarding Alzheimer’s disease [15].  
There was no significant difference regarding 
total plasma tau protein level between the two 
treatment groups. The expression of tau is 
predominantly in brain, but tau can also be found at 
both mRNA and protein level in salivary glands and 
kidney. This is a potential confounder that may help 
explain the difference of total tau protein level 
between brain and plasma. In plasma, the half-life of 
tau appears to be shorter (hours) than in 
cerebrospinal fluid (weeks) [39].  
In conclusion, turmeric extract 
supplementation reduces tau protein level in brain and 
plasma following repetitive traumatic brain injury. The 
most significant effect was found in the pre-treatment 
group. Further studies to demonstrate the effect of 
turmeric extract on the clinical outcome will be 
needed.  
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